Company Overview of Protein Genomics, Inc.
Protein Genomics, Inc. engages in the research, development, and production of biopolymers for applications in wound healing, tissue regeneration, dermal filler, and personal care markets. It produces Elastatropin, a laboratory synthesized form of human tropoelastin, which is a natural precursor of the human elastin in the skin for use in wound healing, anti-aging skin care, and scalp and hair conditioning applications. The company also produces Keracyte, a scalp conditioner that is formulated to stimulate hair follicles to make existing hair shafts thicker, stronger, and longer, as well as contains a proprietary catalytic anti-oxidant prolisel that protects against the damaging effects of U...
2675 West Highway 89A
Sedona, AZ 86336
Founded in 1993
Key Executives for Protein Genomics, Inc.
Scientific Advisor and Director
Compensation as of Fiscal Year 2014.
Protein Genomics, Inc. Key Developments
American Cryostem Corporation and Protein Genomics, Inc. Form Autogenesis Corporation to Support Development of Unique Stem Cell-Based Wound Products
Nov 14 13
American CryoStem Corporation announced the formation of Autogenesis Corporation (Autogenesis) as part of its collaborative agreement to develop wound healing products and other cellular therapies with privately-held Protein Genomics (PGen). Owned 50/50 by the Companies, Autogenesis will serve as a dedicated business unit focused on continuing and accelerating the research and development of innovative new products and biotechnologies that combine American CryoStem's ATcells(TM) (adipose derived regenerative cells) and ACSelerate(TM) cell media culture products with PGen's Elastatropin(R) human-based protein materials. Pursuant to the previously announced Memorandum of Understanding entered into by American CryoStem and PGen in September 2012, and having successfully met certain defined clinical milestones, both companies have agreed to form Autogenesis, an entity to which each have licensed their respective technologies. From this point forward, Autogenesis will be responsible for perpetuating research and development of all prospective new products and technologies and retain ownership of any future intellectual property which results from the combination of ATcells, ACSelerate and Elastatropin.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries